Skip to content

Evaluation of the safety and effectiveness of the MID-C/ApiFix system in adolescent idiopathic scoliosis.

Evaluation of the safety and effectiveness of the MID-C/ApiFix system in adolescent idiopathic scoliosis. - The ApiFix system for the treatment of adolescent idiopathic scoliosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON43676
Enrollment
33
Registered
2015-07-08
Start date
2015-10-08
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal curvature

Interventions

The spinal deformity of the patients will be surgically corrected using the ApiFix system and sequential correction exercises.

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
12 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Adolescent idiopathic scoliosis patients (10 years - 17 years old); 2. Standing X-ray: 40 to 55 degrees Cobb angle, Lenke type 1 or 5, Risser stage 1-4; 3. Lateral bending X-ray: primary curve should be reduced to

Exclusion criteria

Exclusion criteria: 1. Other non-idiopathic form of scoliosis; 2. Primary curve Cobb angle >50 degrees; 3. Adolescent idiopathic scoliosis which is not defined as Lenke type 1 or 5; 4. Previous spine surgery; 5. Known allergy to titanium; 6. Active systemic disease, such as AIDS, HIV, or active infection; 7. Systemic disease that would affect the subject*s welfare or overall outcome of the study, or; 8. Mentally compromised.

Design outcomes

Primary

MeasureTime frame
Effectiveness: 1. Correction of primary curve Cobb angle at 6 months follow-up (percentage and absolute degrees).

Secondary

MeasureTime frame
Safety: 1. Curve progression above or below the implant over time at all follow-ups; 2. Vertebral rotation based on Bunnell Scoliometer; 3. Vertebral rotation based on AP X-ray using the Nash and Moe method [7], and; 4. (Serious) adverse event. Effectiveness: 1. Patient reported outcome (SRS-22); 2. Correction of primary curve Cobb angle to

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)